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https://doi.org/10.1016/j.cell.2021.09.003SUMMARYThe independent emergence late in 2020 of the B.1.1.7, B.1.351, and P.1 lineages of SARS-CoV-2 prompted
renewed concerns about the evolutionary capacity of this virus to overcome public health interventions and
rising population immunity. Here, by examining patterns of synonymous and non-synonymous mutations
that have accumulated in SARS-CoV-2 genomes since the pandemic began, we find that the emergence
of these three ‘‘501Y lineages’’ coincided with a major global shift in the selective forces acting on various
SARS-CoV-2 genes. Following their emergence, the adaptive evolution of 501Y lineage viruses has involved
repeated selectively favored convergent mutations at 35 genome sites, mutations we refer to as the 501Y
meta-signature. The ongoing convergence of viruses in many other lineages on this meta-signature suggests
that it includesmultiple mutation combinations capable of promoting the persistence of diverse SARS-CoV-2
lineages in the face of mounting host immune recognition.INTRODUCTION
In the first 11 months of the SARS-CoV-2 pandemic (December
2019 – October 2020), the evolution of the virus worldwide was in
the context of a highly susceptible new host population (Dear-
love et al., 2020; MacLean et al., 2021). Other than the early iden-
tification of the D614G substitution in the viral Spike protein
(Korber et al., 2020; Plante et al., 2021; Zhang et al., 2020) and
P323L in the viral RNA-dependent RNA polymerase protein (Gar-Cell 184, 5189–vin et al., 2020), both of whichmay have increased viral transmis-
sibility without impacting pathogenesis (Peacock et al., 2021),
few mutations were epidemiologically significant and the evolu-
tionary dynamics of the virus were predominantly characterized
by a mutational pattern of slow and selectively neutral random
genetic drift (Dearlove et al., 2020; MacLean et al., 2021). This
behavior is consistent with exponential growth in a population
of naive susceptible hosts that do not exert significant selective
pressures on the pathogen prior to transmission events5200, September 30, 2021 ª 2021 Published by Elsevier Inc. 5189
Figure 1. SARS-CoV-2 genome map indi-
cating the locations and encoded amino
acid changes of what we considered here
to be signature mutations of V1, V2, and V3
sequences
Genes represented with light-blue blocks encode
non-structural proteins and genes in orange
encode structural proteins: S encodes the Spike
protein, E the envelope protein, M the matrix
protein, and N the nucleocapsid protein. Within
the S-gene, the receptor binding domain (RBD) is
indicated by a darker shade, and the furin cleav-
age site is indicated by a dotted vertical line.
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Article(MacLean et al., 2021). Past pandemics and long-term evolu-
tionary dynamics of RNA viruses attest to the fact that such an
evolutionary ‘‘lull’’ rarely lasts. Indeed, in late 2020, three rela-
tively divergent SARS-CoV-2 lineages emerged in rapid succes-
sion: (1) alpha, B.1.1.7 or 501Y.V1 which will hereafter be
referred to as V1 (Rambaut et al., 2020a), (2) beta, B.1.351 or
501Y.V2 which will hereafter be referred to as V2 (Tegally et al.,
2021), and (3) gamma, P.1 or 501Y.V3, which will hereafter be
referred to as V3 (Faria et al., 2021).
Viruses in each of the three lineages (which will hereafter be
collectively referred to as 501Y lineages) have multiple signature
(or lineage defining) deletions and amino acid substitutions (Fig-
ure 1), many of which impact key domains of the Spike protein:
the primary target of both infection and vaccine-induced immune
responses. While many distinct Spike mutations had been
observed prior to the 501Y lineages, all circulating SARS-CoV-
2 lineages were defined by small numbers of mutations. All of
the 501Y lineages also have significantly altered phenotypes:
increased human ACE2 receptor affinity (V1, V2, and V3) (Nelson
et al., 2021; Starr et al., 2020; Zahradnik et al., 2021), increased
transmissibility (V1, V2, and V3) (Althaus et al., 2021; Faria et al.,
2021; Lubinski et al., 2021; Pearson et al., 2021; Public Health
England, 2020; Volz et al., 2021), substantially increased capac-
ity to overcome prior infection and/or vaccination-induced im-
munity (V2 and V3) (Cele et al., 2021; Garcia-Beltran et al.,
2021; Hoffmann et al., 2021; Shinde et al., 2021; Wibmer et al.,
2021; Wu et al., 2021), and associations with increased virulence
(V1 and V3) (Faria et al., 2021; Horby et al., 2021). Why did the
heavily mutated 501Y lineages all arise on different continents
at almost the same time? Was it due to an intrinsic change in
the capacity of SARS-CoV-2 to adapt, or was it a shift in the
host selective environment extrinsic to the virus?
Evidence that natural selection has played a pivotal role in the
emergence of V1, V2, and V3 can be found in the remarkable
patterns of independently evolved convergent mutations that5190 Cell 184, 5189–5200, September 30, 2021have arisen within the members of these
lineages (Figure 1; Peacock et al., 2021).
One of the most striking of these parallel
changes is a nine-nucleotide deletion
between genome coordinates 11288
and 11296 (here and hereafter all nucleo-
tide and amino acid coordinates refer
to the GenBank reference genome
NC_045512). This deletion is within theportion of ORF1ab that encodes non-structural protein 6
(nsp6): a component of the SARS-CoV-2 membrane-tethered
replication complex that likely influences the formation and
maturation of autophagosomes (Cottam et al., 2011) and de-
creases the effectiveness of host innate antiviral defenses by
reducing the responsiveness of infected cells to, and antago-
nizing the production of, type I interferons (Lei et al., 2020; Miorin
et al., 2020; Xia et al., 2020). Relative to some of the earliest char-
acterized SARS-CoV-2 A and B variants, V1 and V2 viruses have
demonstrably less sensitivity to type I interferons (Guo et al.,
2021; Thorne et al., 2021), and V1 displays greater antagonism
of type I interferon-mediated immune activation during the early
stages of infection in cultured lung epithelial cells (Thorne et al.,
2021). However, it remains unknown whether these characteris-
tics of V1 and V2 viruses are in any way attributable to their
shared 11288–11296 deletion. Independently evolved instances
of this deletion have been repeatedly found prior to the emer-
gence of the 501Y lineages and identical independently evolved
deletions are also found together with other 501Y lineage
signature mutations in the SARS-CoV-2 lineages, B.1.620
(Dudas et al., 2021), B.1.1.318, B.1.525 (https://github.com/
cov-lineages/pango-designation/issues/4), and B.1.526 (Anna-
vajhala et al., 2021). This degree of convergent evolution implies
that, in the context of the B.1.620, B.1.1.318, B.1.525, B.1.526,
and the 501Y lineages at least, the 11288–11296 deletion is likely
highly adaptive.
Additionally, there are four convergent spike gene mutations
that are each shared between members of different 501Y line-
ages. Almost all the spike genes of sequences in these lineages
carry the N501Y mutation at a key receptor binding domain
(RBD) site that increases the affinity of the Spike protein for hu-
man ACE2 receptors by 2.1- to 3.5-fold (Starr et al., 2020;
Yuan et al., 2021; Zahradnik et al., 2021). The vast majority of
V2 and V3 variants and0.3%of more recent samples of V1 var-
iants also have a Spike E484K mutation. Whereas in the
ll
Articlepresence of 501N, 484K has a modest positive impact on ACE2
binding (Starr et al., 2020), when present with 501Y, these muta-
tions together synergistically increase ACE2-RBD binding affin-
ity 12.7-fold (Nelson et al., 2021; Zahradnik et al., 2021).
Crucially, E484K and other mutations at S/484 also frequently
confer protection from neutralization by both convalescent
sera (Greaney et al., 2021a), vaccine-elicited antibodies (Collier
et al., 2021; Wang et al., 2021a, 2021b; Wu et al., 2021), and
some monoclonal antibodies (Greaney et al., 2021a; Starr
et al., 2021;Wang et al., 2021b). There is therefore increasing ev-
idence that viruses carrying the E484K mutation (with or without
501Y) will be able to more frequently infect both previously in-
fected and vaccinated individuals (Collier et al., 2021; Wang
et al., 2021a, 2021b; Wu et al., 2021).
A third RBD site that is mutated in both V2 and V3 is S/417.
Whereas V2 sequences generally carry a K417N mutation, V3
sequences carry a K417T mutation. Although both the K417N
and K417T mutations can reduce the affinity of Spike for
ACE2, in conjunction with the N501Y and E484K mutations,
ACE2 binding is restored to that of wild-type Spike (Yuan et al.,
2021). K417N and K417T also both have moderately positive im-
pacts on Spike expression (Starr et al., 2020), and these and
other mutations at S/417 provide modest protection from
neutralization by some convalescent sera (Greaney et al.,
2021a; Wang et al., 2021b), vaccine-induced antibodies (Wang
et al., 2021b), and some neutralizing monoclonal antibodies
(Starr et al., 2021; Wang et al., 2021b; Wibmer et al., 2021).
A fourth spike gene mutation that is shared by48% of V2 se-
quences and by all V3 sequences is L18F. This amino acid
change is predicted to have a modest impact on the structure
of Spike (Nguyen et al., 2021) and also protects from some
neutralizing monoclonal antibodies (McCallum et al., 2021). Vi-
ruses carrying the L18F mutation increased in prevalence from
the start of the pandemic and now account for10%of sampled
SARS-CoV-2 sequences.
These five convergent mutations in different rapidly spreading
SARS-CoV-2 lineages serve as compelling evidence that they
each, either alone or in combination, provide some significant
fitness advantage. The individual and collective fitness impacts
of the other signature mutations in V1, V2, and V3 remain un-
clear. A key way to infer the fitness impacts of these mutations
is to examine patterns of synonymous and non-synonymous
substitutions at the codon sites where the mutations occurred
(Kosakovsky Pond and Frost, 2005). Specifically, it is expected
that the most biologically important of these mutations will
have occurred at codon sites that display substitution patterns
across the wider SARS-CoV-2 phylogeny that are dominated
by non-synonymous mutations (i.e., mutations that alter en-
coded amino acid sequences), patterns that are indicative of
positive selection.
Here, using a suite of phylogenetics-based natural selection
analysis techniques, we examine patterns of positive selection
within the protein coding sequences of viruses in the V1, V2,
and V3 lineages which, together with mutation frequency
changes over time, we use to identify the specific mutations
that are at present most likely contributing to the increased
adaptation of these lineages. We find that the emergence of
the 501Y lineages coincidedwith amarked global change in pos-itive selection signals, indicative of a general shift in the selective
environment within which SARS-CoV-2 is evolving. Against this
backdrop, the 501Y lineages all display evidence of substantial
ongoing adaptation involving, in many cases, mutations at posi-
tively selected genome sites that both converge on mutations
seen in other 501Y lineages and are rapidly rising in frequency
in different lineages. This pattern suggests that viruses in all three
lineages are presently still climbing very similar adaptive peaks,
and, therefore, that viruses in all three lineages are likely in the
process of converging on a similar adaptive endpoint.
RESULTS AND DISCUSSION
In late 2020, therewas a detectable shift in the selective
pressures acting on circulating SARS-CoV-2 variants
Analyses of positive selection on SARS-CoV-2 genomes under-
taken prior to the emergence of 501Y lineages revealed muta-
tional patterns dominated by neutral evolution (MacLean et al.,
2021). There were, however, indications that some sites in the
genome had experienced episodes of positive selection (Garvin
et al., 2020; Korber et al., 2020; Plante et al., 2021; Zhang et al.,
2020). Through regular analyses of global GISAID data (Elbe and
Buckland-Merrett, 2017) starting in March 2020, we tracked the
extent and location of positive and negative selective pressures
on SARS-CoV-2 genomes (Figure 2). The power of these ana-
lyses to detect evidence of selection acting on individual codon
sites progressively increased over time with rising numbers of
sampled genome sequences and sequence diversification.
Even accounting for this expected increased power of detec-
tion, it is evident that a significant shift in selective pressures
occurred 11 months after SARS-CoV-2 cases were first re-
ported in Wuhan City in December 2019. Specifically, during
November 2020 this change in selection pressures manifested
in substantial increases in the numbers of SARS-CoV-2 codon
sites that were detectably evolving under both positive and
negative selection. This increase accelerated through February
2021, with sites found to be evolving under diversifying positive
selection in several genomic regions (p % 0.01 with the FEL se-
lection detection method [Kosakovsky Pond and Frost, 2005])
rapidly increasing in density for several key genes including S,
nsp2, and nsp6 (Figure 2A; Figure S1). This increase cannot be
fully explained by increased sampling at later time points, as
our estimates of positively selected site densities are corrected
to account for variations in phylogenetic signal (i.e., they are frac-
tions of the total length of internal tree branches [MacLean et al.,
2021]). This sudden increase in the density of sites that were
detectably evolving under positive selection coincided with
epidemic surges in multiple parts of the world in both hemi-
spheres, many of which were driven by the emerging V1, V2,
and V3 lineages.
Among the 37 signature mutation sites in V1, V2, and V3 (Fig-
ure 1), 14 were detectably evolving under positive selection in
November 2020, whereas this number increased to 22 by
January 2021 and 30 by April 2021 (Figure 2C). The only signa-
ture mutation shared between any of the three 501Y lineages
that was detectably evolving under positive selection before
November 2020 was S/18, which was detected for the first
time in August 2020.Cell 184, 5189–5200, September 30, 2021 5191
Figure 2. Signals of positive and negative
selection at individual codon sites that
were detectable with the FEL method at
different times between March 2020 and
April 2021 applied to sequences sampled
over 90-day intervals
The plotted dates show the end of 90-day periods.
(A and B) The gene-by-gene/per Kb/per unit tree
length density of codons that are detectably
evolving under positive/negative selection be-
tween March 2020 and February 2021. Whereas
genes for which the maximum observed density of
positively/negatively selected sites was reached in
February 2021 are shown with thicker lines, genes
with associated trees that have a total length
shorter than 0.5 subs/site for a given time period
are not shown. A version of (A) with all genes dis-
played separately is given in Figure S1.
(C) Signals of positive selection detected at 37 V1,
V2, and V3 signature mutation sites between
March 2020 and April 2021. Also included for
reference are sites previously detected to be
evolving under positive selection such as S/614,
the site of the D614G mutation that is present in all
three of the 501Y lineages, S/5, and RdRp/P323L
(ORF1b/314). Circles indicate the statistical sig-
nificance of the FEL test with red indicating posi-
tive selection and blue indicating negative selec-
tion. The vertical line indicates December 1, 2020,
the approximate date when the importance of the
V1 and V2 lineages were first noticed.
See also Figure S1.
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ArticleOur regular tracking of positively selected SARS-CoV-2 codon
sites prior to November 2020 therefore yielded no clear indica-
tions that non-synonymous substitutions at the crucial RBD
sites, S/417, S/484, and S/501 (the other key convergent signa-
ture mutation sites in the 501Y lineages), provided SARS-CoV-2
with any substantial fitness advantages prior to November 2020.
Instead, the sporadic weak selection signals that these analyses
yielded between July and November were of adaptive amino
acid substitutions in the Spike N-terminal domain (S/18, and
the V3 signature sites, S/26 and S/138), near the furin cleavage
site (the V3 signature site, S/655, and the V1 signature site
S/681), and in the C-terminal domain (the V1 signature site,
S/1118, and the V3 signature site, S/1176). Conversely, for
much of the latter half of 2020 the relatively strong and consis-
tently detected selection signals at the V1 signature site, N/3,
and the V2 signature sites, ORF1ab/265 (nsp2 codon 85) and
ORF3a/57, clearly indicated that some substitutions at these
sites were likely adaptative.
Taken together, these patterns of detectable selection sug-
gest that the adaptive value of signature 501Y lineage RBD mu-
tations may have only manifested after a selective shift that
occurred shortly before November 2020.
Signals of selectionwithin the V1, V2, and V3 lineages up
until March 2021
We initially restricted our selection analyses to only consider mu-
tations arising within V1, V2, and V3 lineage sequences sampled
before April 2021 to assess the adaptive processes at play within
these lineages during and immediately after the perceived shift5192 Cell 184, 5189–5200, September 30, 2021in the SARS-CoV-2 selective landscape in late 2020. We were
specifically interested in identifying positive selection signals at
individual codon sites that reflected these ‘‘early’’ selective
processes.
We collected all sequences assigned to B.1.1.7 (V1), B.1.351
(V2), and P1 (V3) PANGO lineages (Rambaut et al., 2020b) in
GISAID (Elbe and Buckland-Merrett, 2017) as of April 20, 2021
and tested these sequences for evidence of positive selection
at individual codon sites using MEME (Murrell et al., 2012) and
FEL (Pond et al., 2006). Both of these methods were restricted
to analyzing mutations that mapped to internal branches of V1,
V2, and V3 phylogenetic trees: i.e., mutations that almost
certainly would have only arisen before mid-March 2021.
These analyses revealed evidence of positive selection at 151
individual codon sites (at p < 0.05) across all lineages including
80 in V1, 41 in V2, and 37 in V3 (Table S1). This is indicative of
substantial adaptation of V1, V2, and V3 sequences between
the time of their emergence and March 2021.
Signals of ongoing mutational convergence at signature
mutation sites
Notable among the lineage-specific positive selection signals
were 22/151 at lineage defining mutation sites: 8/11 of the V1
signature sites, 4/14 of the V2 ones, and 13/17 of the V3 ones
(Figure 3 and see underlined codon-site numbers in Figure 1).
Given that (1) each lineage was defined by the signature muta-
tions along the phylogenetic tree branch basal to its clade, and
(2) that these basal branches were included in the lineage-spe-
cific selection analyses, these selection analysis results were
Figure 3. Genome sites where signature and convergent mutations
occur within the 501Y lineage sequences
Sites detectably evolving under positive selection along internal branches
(MEME p % 0.05) of the V1, V2, and V3 phylogenies are indicated with red
icons. We restricted our analysis to data collected up to April 2021 to focus on
interpreting predictive positive selection signals arising from mutations
occurring before March 2021, which could then be corroborated by examining
mutation frequency data from later months. Labels within the colored
blocks indicate amino acid substitutions with block colors indicating model-
based predictions of the probable evolutionary viability of the observed amino
acid substitutions based on the numbers of times these substitutions have
been observed in related coronaviruses that infect other host species. The
absence of color indicates unprecedented substitutions, red indicates highly
unusual substitutions, and green indicates common substitutions seen at
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Articlebiased in favor of detecting the signature mutations as evolving
under positive selection. We therefore used the selection results
for signature mutation sites only to identify the signature muta-
tions that, relative to the background reference sequences,
were evolving under the strongest degrees of positive selection
during or before March 2021.
Most noteworthy of the 22 signature mutation sites that dis-
played the strongest evidence of lineage-specific positive selec-
tion are codons S/18, S/80, S/417, S/501, S/655, and S/681 in
that all are either suspected or known to harbor mutations with
potentially significant fitness impacts (Garry et al., 2021; Greaney
et al., 2021b, 2021a; Lubinski et al., 2021; McCallum et al., 2021;
Starr et al., 2020; Wang et al., 2021a, 2021b; Zahradnik
et al., 2021).
Before March 2021, there were particularly interesting muta-
tional dynamics at codon S/18 in the V1 lineage. Whereas the
L18F mutation is effectively fixed in all currently sampled V3 line-
age sequences, it occurred (and persisted in descendent vari-
ants) at least twice in the V1 lineage and at least four times in
the V2 lineage. S/18 falls within multiple different predicted
CTL epitopes (Campbell et al., 2020) and the L18F mutation is
known to reduce viral sensitivity to some neutralizingmonoclonal
antibodies (McCallum et al., 2021). An F at residue S/18 is also
observed in 10% of other known Sarbecoviruses and the L18F
mutation was the 28th most common in sampled SARS-CoV-2
genomes on June 4, 2021. Having occurred independently
numerous times since the start of the pandemic, S/18 has also
been detectably evolving under positive selection in the global
SARS-CoV-2 genome dataset since August 2020 (Figure 2C).
Similar convergence patterns to those observed at S/18 could
be seen at 17 other signature mutation sites that, before March
2021, were detectably evolving under positive selection in either
the global (Figure 2C) or lineage-specific (Figure 3) datasets:
ORF1a/265, ORF1a/1188, S/26, S/138, S/215, S/417, S/484,
S/501, S/655, S/681, S/701, S/716, S/1027, S/1176, ORF3a/
57, N/205, and N/235.
Of these, S/655, S/681, S/701, and S/716 are noteworthy in
that they fall within 30 residues of the biologically important
Spike protein furin cleavage site (S/680 to S/689). Whereas
some V2 and V3 sequences had, by March 2021, independently
acquired the signature V1mutations, P681H and T716I, some V1
and V2 sequences had independently acquired the V3 signature
mutation, H655Y, and some V1 sequences had independently
acquired the V2 signature mutation, A701V. Additionally,
whereas a convergent A701V mutation is also found in the
B.1.526 and S/E484K carrying lineage that was first identified
in New York (Annavajhala et al., 2021), P681H is found in the
S/E484K and S/N501Y carrying P.3 lineage first identified in
the Philippines (Tablizo et al., 2021), and both S/H655Y and S/
P681H are found in the highly mutated S/E484K carrying
A.VOI.V2 lineage first identified in Tanzanian travelers (de Oli-
veira et al., 2021).
Any of H655Y, P681H, A701V, or T716I might directly impact
the efficiency of viral entry into host cells (Garry et al., 2021).homologous sites in non-SARS-CoV-2 coronaviruses. ORF8 signals have
been excluded.
See also Figure S2.
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ArticleSARS-CoV-2 variants with deletions of the furin cleavage site
have reduced pathogenicity (Johnson et al., 2021; Lau et al.,
2020) and the P681H mutation—which falls within this site—
likely increases the efficiency of furin cleavage by replacing a
less favorable uncharged amino acid with amore favorable posi-
tively charged basic one (Garry et al., 2021; Lubinski et al., 2021).
Whereas sites S/655 and S/681 are also detectably evolving un-
der positive selection in at least one of the lineage specific data-
sets, S/655, S/681, A/701, and S/716 are all detectably evolving
under positive selection in the March and April 2021 global
SARS-CoV-2 datasets; important additional indicators that are
consistent with the H655Y, P681H, A701V, and T716I mutations
being adaptive.
Non-convergent mutations at signature mutation sites
might still be evolutionarily convergent
In addition to the 17 signaturemutation sites displaying evidence
of both convergent mutations between the V1, V2, and V3 line-
ages, and positive selection in the global and/or lineage-specific
datasets, four signature mutation sites with lineage-specific sig-
nals of positive selection (S/20, S/138, S/215, and S/570; Fig-
ure 1) display evidence of predominantly divergent mutations
(at the amino acid replacement level), where the same site is
mutated as in another lineage, but to a different amino acid (Fig-
ure 3). A fifth site, S/80, displays evidence of both convergent
and divergent mutations. All but S/20 are also detectably
evolving under positive selection in the global SARS-CoV-2 da-
taset (Figure 2).
The diverging mutations at these five sites might also be
contributing to the overall patterns of evolutionary convergence
between the lineages; just via different routes. Four of these sites
(S/20, S/80, S/138, and S/215) fall within a portion of the Spike
N-terminal domain that is an ‘‘antigenic supersite’’ targeted by
multiple monoclonal and infection-induced neutralizing anti-
bodies (McCallum et al., 2021). It is therefore plausible that these
sites are evolving under immunity-driven diversifying selective
pressures. In this regard, while mutations at S/20, S/80, S/138,
S/215, and S/570 in different lineages do not predominantly
converge on the same encoded amino acid states, they could
nevertheless still be convergent on similar fitness objectives (im-
mune escape or compensation for the fitness costs of other mu-
tations): such as is likely the case with the also not strictly
convergent V2 K417N and V3 K417T signature mutations (Grea-
ney et al., 2021b, 2021a; Nelson et al., 2021).
Positive selectionmay be driving further convergence at
non-signature mutation sites
In addition to lineage-specific signals of positive selection being
detected at 22 of the signature mutation sites that characterize
each of V1, V2, and V3 (Figure 1), such signals were also de-
tected in lineage-specific datasets at 129 non-signature muta-
tion sites (Table S1). As with the positively selected signature
mutation sites, these selection signals are based on mutations
that map to internal V1, V2, and V3 tree branches and likely
reflect selective processes operating before mid-March 2021.
To test whether positive selection acting at these 129 codon
sites might have favored convergent amino acid changes across
the three lineages, we examined mutations occurring at these5194 Cell 184, 5189–5200, September 30, 2021sites for evidence of convergence between two or more of the
lineages. This revealed the occurrence of convergent mutations
between sequences in different lineages at 28/129 (21.7%) of
these sites, including ten in ORF1a, seven in the N-gene, five in
the S-gene (Figure 3), three in ORF3A, and three in ORF1b
(Figure 3).
The lineage-specific positive selection signals detected at
these 28 sites reflect repeated convergent non-synonymousmu-
tations within each lineage that likely increase the fitness of the
genomes in which they occur. Accordingly, 18/28 of the codons
where these inter- and intra-lineage convergent mutations occur
were also detectably evolving under positive selection within the
April global SARS-CoV-2 dataset (FEL p < 0.05; Figure S2). This
concordance between the lineage-specific and global selection
signals is strong evidence that an appreciable proportion of the
convergent non-signature site mutations are broadly adaptive
(as opposed to being only epistatically adaptive in the context
of 501Y lineage virus genomes).
The degree of overlap between non-signature mutation sites
detectably evolving under selection in the V1, V2, and V3 line-
ages and displaying evidence of inter-lineage convergent muta-
tions (Figure 3; Table S1) cannot be adequately explained by
chance alone. Restricting ourselves only to variable sites that
are shared between lineages (i.e., just those sites where it was
possible to detect selection and/or convergent mutations) and
the numbers of selected sites in each lineage, we conducted a
permutation test for the numbers of detectable convergent, posi-
tively selected non-signature site mutations between each pair
of lineages. Overlap by chance can be rejected for V1/V2 (p <
0.001), V1/V3 (p = 0.002), and V2/V3 (p = 0.002). This pattern
supports the hypothesis that all three lineages are at present
accumulating convergent non-signature site mutations that are
contributing to their ascent of the same fitness peak.
Changes inmutation frequencies sincemid-March 2021
corroborate the inferred fitness advantages of
convergent mutations at positively selected
genome sites
Although it is clear that in the regions of theworld where the prev-
alence of 501Y lineage viruses have increased since December
2020, these viruses have had substantial fitness advantages
over the SARS-CoV-2 variants that preceded them, it remains
unclear what the precise biological advantages were. The two
most likely, non-exclusive, reasons for their increased fitness
are (1) that they were better at infecting people that had been
previously infected (V2 and V3) (Cele et al., 2021; Garcia-Beltran
et al., 2021; Wibmer et al., 2021; Wu et al., 2021) and/or (2) that
they were more transmissible (V1, V2, and V3) (Faria et al., 2021;
Pearson et al., 2021; Volz et al., 2021).
While it is likely that all the convergent mutations that are
detectable at positively selected sites (Figure 3) impact SARS-
CoV-2 transmissibility and/or immune escape in at least some
specific situations, it remains unclear what the relative fitness im-
pacts of particular mutations at these sites are. It is, however, ex-
pected that population-wide frequencies of newly arising muta-
tions that directly contribute to increased fitness should, at least
initially, increase at a rate that is proportional to the magnitude of
their fitness contribution. We therefore tested for changes in the
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signature mutation sites represented in Figure 3, and the full
complement of 37 signature substitution mutation sites found
in the 501Y lineage viruses (Figure 1). Specifically, this involved
partitioning V1, V2, and V3 sequences deposited in GISAID by
June 1 into ‘‘early’’ and ‘‘late’’ datasets that respectively con-
tained sequences sampled before and after March 15, 2021: a
date by which all of the internal branch mutations that yielded
the detectable positive selection signals in our lineage-specific
selection analysis datasets (i.e., those represented in Figure 3
and Table S1) would have already arisen. The frequencies of mu-
tations evident at the 37 signature and 28 non-signature muta-
tion sites were then compared between each of the V1, V2,
and V3 early and late dataset pairs.
Over 2-fold increases in frequency between March 15, and
June 1, 2021 were detected in at least one of the three 501Y lin-
eages for at least one of the observed mutations at 29/65 of the
analyzed genome sites (these increases are all individually statis-
tically significant in 232 contingency tables using the conserva-
tive Bonferroni multiple testing correction). Among these 29 sites
are 20 where mutations in one (at 15 sites) or two (at five sites) of
the 501Y lineages first converged on a signature mutation that
characterizes a different 501Y lineage and then proceeded to
double in frequency between March 15 and June 1, 2021 (Table
S2), an indication that the convergence mutations at these 20
sites may have each provided a fitness advantage. Based on
the observed degree of frequency increases, mutations such
as ORF1a/1708D (corresponding to nsp3/890D with 15.8 and
>12.0-fold increases in V2 and V3, respectively), S/26S (>13-
fold increase in V2), S/716I (3.7 and >13.5-fold increases in V2
and V3, respectively), S/1027I (>44-fold increase in V2),
S/1118H (4.0 and >20-fold increases in V2 and V3, respectively),
S/1176F (19.5-fold increase in V2), and ORF3/171L (11.9-fold in-
crease in V3) are the signature mutations that, in addition to the
ORF1a/3675-3677Del, S/18F, S/417N/T E484K, and S/501Y
mutations, are likely to have the greatest positive impact on
the fitness of the 501Y lineage viruses within which they occur.
Similarly, among the nine positively selected sites where non-
signature mutations both converge between viruses in two or
more of the 501Y lineages and then more than double in fre-
quency between March 15 and June 1, 2021, ORF1b/1522I (cor-
responding to Heicase/590I with 1.9-, 12.7-, and 4.8-fold in-
creases in V1, V2, and V3, respectively), S/98F (2.5-, 5.3-, and
>6.0-fold increases in V1, V2, and V3, respectively), and E71T/
R (respectively 5.8- and >10-fold increases in V1) are likely the
most fitness-enhancing mutations.
In total, 20/47 of the analyzed convergent mutations that were
suggested by our global and lineage-specific positive selection
analyses to have contributed to the fitness of 501Y lineage vi-
ruses prior to March 2021 more than doubled in frequency in
at least one of the lineages between 15 March and June 1,
2021. The June 2021 dataset revealed a further nine previously
undetected convergent mutations at 501Y lineage signature
sites (ORF1a/1001I, ORF1a/1655N, ORF1a/1708D, ORF1b/
970, S/215, S/1118, S/1176F, E/71L, and N/205; Table S2) that
were associated with positive selection signals in the global da-
taset (Figure 4) and which also more than doubled in frequency
between March 15 and June 2021. Of all the 501Y lineage muta-tions that have so far been observed, the convergent mutations
at these 29 sites have the strongest corroborating evidence sup-
porting their individual and/or collective contributions to the
ongoing adaptation of 501Y lineage viruses during the present
phase of the pandemic.
Where is the evolution of the 501Y lineages headed?
Regardless of how exactly each of these 29 convergent muta-
tions impact the fitness of 501Y lineage viruses, it is apparent
that the evolution of these viruses will likely involve further selec-
tion-driven mutational convergence at these sites both between
viruses within individual lineages, and between viruses in the
different lineages. Based on our selection analyses, the conver-
gence patterns that we have so far detected, and the rises in fre-
quencies between March 15 and June 1, 2021 of 501Y viruses
carrying particular convergent mutations, we can propose a
‘‘meta-signature’’ for the most adaptive amino acid states at
35 sites within 501Y lineage genomes (Table S3; Figure 4). In
addition to the 29 convergent mutations that displayed fre-
quency increases between March 15 and June 1, 2021, the
meta-signature includes deletion mutations at ORF1a/3675–
3677, S/69–70, S/144, and S/241–243 (which, while displaying
convergence between the different 501Y lineages, were not
amenable to selection analyses) and the convergent signature
substitutions L18F, K417N/K, and N501Y (which were already
at high frequencies inmultiple 501Y lineages byMarch 15, 2021).
Before March 2021 most V1, V2, and V3 viruses respectively
carried 10, 13, and 11 of the mutations within this meta-signa-
ture. By June 1, 2021, 17 different V1 variants (represented by
53 sequenced genomes) matched 13 of the meta-signature
sites, two different V2 variants (represented by 20 sequenced
genomes) matched 16 of the sites, and one V3 variant (repre-
sented by 4 sequences) matched 14 of the sites: i.e., in all three
lineages viruses were present that had taken three additional
mutational steps that converged on the meta-signature.
Given that 19/35 of themeta-signature sites are in Spike, these
patterns can be best illustrated by examining convergence on
the meta-signature Spike sites within the different 501Y lineages
since October 2020 (Figure 5). Whereas the prototype V1, V2,
and V3 genomes, respectively, carried only six, six, and nine of
the 19 Spike mutations in the meta-signature, by June 1, 2021
V1, V2, and V3 variants had arisen that, respectively, carried
10, 10, and 11 of these mutations (Figure 5).
Beyond the three 501Y lineages, we compared degrees of
convergence on the 501Y meta-signature of all SARS-CoV-2
genome sequences in GISAID on June 1, 2021 that were classi-
fied as belonging to lineages designated by either Public Health
England or the US CDC as variants of concern (VOCs), variants
of interest (VOI) or variants under investigation (VUI; Table S3).
All of these lineages had viruses assigned to them that matched
at least one of the meta-signature mutations. The lineages con-
taining sequences with the most matches were B.1.526 and
B.1.621 (both with modal matches = 5 and maximum = 7), sug-
gesting that they too are possibly scaling the same fitness peak
as the 501Y lineage viruses.
Other prominent VOC, VOI, and VUI lineages, however, had
very few matches. For example, the best-matched sequences
within the B.1.617.2, P.2, and R.1 lineages each had only threeCell 184, 5189–5200, September 30, 2021 5195
Figure 4. Selection signals evident in the global data at the subset of sites identified by the positive selection, convergence, and mutation
frequency change analyses as likely contributing to the fitness of the 501Y lineage viruses: a subset of sites and their associated amino acid
states that we refer to as the 501Y lineage meta-signature
The strengths of detected selection signals (with the IFEL method) are indicated by the sizes of the red dots. Selection tests were performed on sequence data
collected within the preceding three months (i.e., red spots plotted in April reflect the analysis of sequences sampled between January 1 and April 1). The vertical
bar indicates December 1, 2020. The global frequencies of the represented mutations are indicated in gray. These frequencies are strongly biased by, and
therefore track in many instances, the rapid rise of V1 viruses in the UK, Europe and North America: the regions of the world responsible for >90% of all SARS-
CoV-2 genome sequencing between January and June 2001.
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Articlematches to the meta-signature (with modal matches in each be-
ing one, two, and one, respectively), implying that viruses in
these lineages are likely scaling a different fitness peak to the
one that the 501Y lineage viruses are on. While in the
B.1.617.1 lineage (the sister lineage to B.1.617.2), most se-
quences only contain one match to the meta-signature, there
are some sequences in this lineage that match it at six sites.
This suggests that at least some sub-lineages within B.617 are
climbing the same fitness peak as the 501Y lineage viruses.
The non-501Y lineage SARS-CoV-2 isolates that most closely
match the meta-signature are found within B.1.620, a lineage
first detected in Lithuania (but likely originating in Central Africa)
that is presently not considered a VOI, VOC, or VUI (Dudas et al.,
2021). Whereas the modal number of meta-signature matches
for members of B.1.620 is eight (3675–3677Del in ORF1a; 26S,
69–70Del, 241–243Del, 484K, 681H, 1027I, 1118H in Spike),
some sequences within the lineage have ten matches, suggest-
ing both that the members of this lineage are on the same fitness5196 Cell 184, 5189–5200, September 30, 2021peak as the 501Y lineage viruses, and that they too are discov-
ering predictable paths to its summit.
We therefore anticipate that the culmination of the currently
ongoing evolutionary convergence of 501Y lineage viruses will
yield a succession of variants possessing increasing subsets of
501Y lineage meta-signature mutations. The most important
issue is not whether we correctly predict the emergence of a
variant carrying mutations at every one of the 35 meta-signature
sites. It is rather that the convergent mutations that are
continuing to arise, both in members of the 501Y lineages and
those of lineages such as B.1.620, B1.621, and B1.526, imply
that all these viruses are presently on, and are actively scaling,
the same broad peak in the fitness landscape. Whatever
SARS-CoV-2 variants eventually summit that peak could be a
considerably bigger problem for us than any we currently
know, in that they might have any combinations of increased
transmissibility, altered virulence and/or increased capacity to
escape population immunity.
Figure 5. Weekly changes in the counts of sequences displaying multiple convergence mutations at the 19 sites in Spike predicted by our
analyses to provide 501Y lineage viruses with selective advantages
This 501Y lineagemeta-signature includes the followingmutations: 18F, 26R/L/S, 69-70Del, 98F, 138HY, 144Del, 215G/H/V/Y, 241-243Del, 417N/T, 484K, 501Y,
655Y, 681L/R/H, 701V, 716I, 1027I, 1118H, 1176F, 1264L. The matches plots (top row) indicate the numbers of sequenced V1, V2, and V3 genomes carrying a
given number of matching mutations at sites on this list: archetypical V1, V2, and V3 sequences, respectively, have Spike sequences with six, six, and nine
matches. The signature sequence plots (bottom row) indicate the counts of particular V1, V2, and V3 Spike sequence haplotypes with the highest numbers of
matches and indicate the subsets of matching mutations in these haplotype sequences. The signature lists included together with these plots indicate the subset
of mutations at the 19 convergence list sites that are present in the different Spike haplotype sequences represented in the plots. ‘‘.’’ symbols indicate the
absence of a convergence list mutation, ‘‘-’’ symbols indicate the occurrence of convergence list deletion mutations and letters indicate the presence of
convergence list amino acid substitutions.
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ArticleAlthough only time can test the accuracy of this prediction, it
should also be possible using in vitro evolution to infer some
amino acid sequence features at the adaptive summit of this
fitness peak. An obvious, albeit potentially controversial,
approach would be to use replicated, laboratory infections of
either synthesized or sampled live viruses carrying complements
of mutations that are representative of the current standing di-
versity within the V1, V2, and V3 lineages. In the presence of
mixed sera from multiple previously infected and/or vaccinated
individuals these infections would create the appropriate condi-
tions both for genetic recombination to occur, and for selection
to rapidly sort multiple recombination-generated combinations
of input immune evasion, cell entry, and replication impacting
mutations. Although the chimeras that ultimately dominate these
in vitro infections will doubtlessly be cell-culture optimized (as
opposed to transmission between, and replication within, hu-
mans optimized), they should nevertheless carry many combina-
tions of mutations that will be relevant to the continuing
pandemic and that should include some of the most concerning
mutation combinations that might arise before the pandemic
concludes: perhaps particularly so when 501Y lineage viruses
start frequently recombining with each other. Even if the con-
cerning combinations that are discovered are only triplets or
quartets of mutations, these would still be invaluable hints at
what we should start looking for when it comes to trawling the
rapidly growing pool of SARS-CoV-2 genomic surveillancedata for potential vaccine escape mutants and other potentially
problematic variants.
Limitations of the study
Selection analyses employed here are notwell suited to detecting
certain types of selection (e.g., directional selection), for which
other specialized techniques can be used (e.g., the DEPS
method). Despite our stringent filtering, some of the selection sig-
nals detected may have been false positives attributable to
sequencing errors, undetected genetic recombination and/or
inaccurate phylogenetic inference. Similarly, given the relatively
lowdivergenceofSARS-COV-2genomes, lackof power todetect
positive selection (i.e., enough synonymous and non-synony-
mous substitutions occurring at individual codon sites) was, and
will remain, a persistent issue with detecting positive selection in
SARS-CoV-2 sequences. Further, all of our comparative analyses
were subject to temporal and spatial sampling biases, and coun-
try-to-country heterogeneity in time lags between when viruses
were sampled, and their sequences became publicly accessible.
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ArticleAll analyzed multiple sequence alignments containing compressed de-identified gene or gene segment sequences have been
deposited at Zenodo and are publicly available as of the date of publication. DOIs are listed in the key resources table.
All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOIs are listed in the key
resources table.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
METHOD DETAILS
Global SARS-CoV-2 dataset preparation
Since genes/peptides are the targets of selection, unless specified otherwise here and hereafter, all analyses were performed on sin-
gle genes (e.g., the spike gene) or peptide encoding gene segments (e.g., nsp3). We developed an open-source bioinformatics work-
flow to handle large volumes of sequencing data (> 1,000,000 sequences) in a systematic and scalable manner (https://covid19.
galaxyproject.org/). Until SARS-CoV-2 emerged in 2019, analyses of natural selection using a few thousand viral sequences would
be considered ‘‘large scale’’ (Murrell et al., 2013). Our approach represents a substantial technical advance over the previous state of
the art. Because we were also interested in temporal trends in selective pressures, we partitioned all the sequences into three-month
intervals based on the date of sampling, and analyzing sliding temporal windows, starting on the 1st of each month fromMarch 2020
to May 2021:
1. We downloaded and curated GISAID sequence data, removed sequences that contained too many ambiguous or unresolved
nucleotides, and identified all unique haplotypes for each of the 23 genomic regions that were then analyzed individually (3C, E,
endornase, exonuclease, helicase, leader, M, methyltransferase, N, nsp2, nsp3, nsp4, nsp6, nsp7, nsp8, nsp9, nsp10, ORF3a,
ORF6, ORF7a, ORF8, RdRp, S).
2. We translated each unique haplotype into an amino-acid sequence via a procedure that allows correction of out-of-frame
sequencing errors (while not common, there are several thousand sequences in GISAID which have these errors), following
which these translated sequences were mapped to the NCBI SARS-CoV-2 genome reference using the bealign tool from
the BioExt package (github.com/veg/bioext) using the scoring matrix developed for rapidly evolving RNA viruses (Nickle
et al., 2007). We did not keep track of insertions relative to the reference genome (this is common practice in the field, since
there are no widely circulating strains with evidence of insertions). Therefore, mapping to the reference sequences of individual
gene and gene segments generated multiple sequence alignments that were suitable for downstream analyses. These data
were directly used for tabulating mutation frequencies and tracking haplotypes with mutations that matched specific mutation
signatures (for example, see https://observablehq.com/@spond/spike-trends)
3. Direct comparative analyses of tens or hundreds of thousands of haplotypes is technically very challenging but is not neces-
sary with respect to extracting the majority of the available selection signal. This is due to two factors. First, much of the vari-
ation in individual genomes is either artifactual (sequencing or assembly errors), or not biologically informative (occurs only in a
few strains). Second, analyses in such settings need to account for a well-known feature of viral evolution (Poon et al., 2007)
where terminal branches include ‘‘dead-end’’ mutation events within individual hosts which, although maladaptive or delete-
rious at the population level (Pybus et al., 2007), have not been ‘‘seen’’ by natural selection. Mutations that map to internal tree
branches on the other hand are far less likely to be severely maladaptive since they must include at least one transmission
event. We therefore implemented three layers of compression to reduce the numbers of sequence haplotypes that needed
to be subjected to comparative analyses.
1. We did not retain copies of identical sequences. Instead, all identical sequences were represented by a single haplotype. This
was because comparative phylogenetic analyses of evolutionary rates do not gain information from the inclusion of identical
sequences.
2. We filtered putative sequencing errors and ‘‘problematic’’ sequences. A mutation that occurs in X out of N total sequences
(counting all sequences, not just the unique ones) was considered to be an ‘‘error’’ if the binomial probability of observing X
or more error mutations at a site was sufficiently high (in our case p > 0.999) assuming a sequencing error rate of 1:10,000.
For example, if N = 500,000, then X would be 29. This means that unless a mutation occurred in 30/500,000 or more individual
sequences, it would have been treated as an error and replaced with a phylogenetically uninformative gap character (i.e., ‘‘-’’).
One exception to this rule occurredwhen two raremutations a and b that would have been filtered out if considered in isolation,
occurred together in more than one sequence (i.e., they represented rare linked mutations); we retained such mutations
because the probability of coincidental doublets occurring by chance is quadratically small. Additionally, assuming that the
distribution of differences from reference sequences across all sequences had a mean, M, and standard deviation, D, we
further removed all sequences that had more than M + 5D mutations. These sequences were deemed to be ‘‘unusually’’
mutated and potentially the product of sequencing device contamination, extensive sequencing errors, and/or real/artifactual
sequencing assembly-associated recombination.
3. We grouped the remaining filtered haplotypes into clusters based on complete linkage using TN93 distances for computing
pairwise sequence similarities (Rhee et al., 2019); sequences were placed in a cluster if and only if all of the pairwise distancese2 Cell 184, 5189–5200.e1–e4, September 30, 2021
ll
Articlebetween them were% d, where d is a gene-specific threshold, e.g., d = 0.001 for S. All the sequences belonging to the same
cluster were represented by a single ‘‘median’’ sequence from the cluster.
4. For example, consider Spike sequences sampled between 01 March 2021 and 31 May 2021. 534,345 sequences passed the
initial step 1 filter. Following the step 3a filter, these were reduced to 63,559 unique haplotypes. Following error correction and
haplotype recompression in step 3b (where ‘-’ characters were introduced to reflect corrected putative sequencing errors and
where ‘-’ matched any resolved characters) 41,103 haplotypes remained. In step 3c these were then compressed down to
5,147 clusters, each yielding a single representative haplotype sequence that was used for downstream selection analyses.
4. We next reconstructed phylogenetic trees for the remaining haplotype sequences using RapidNJ (Simonsen et al., 2008).
5. We used HyPhy v2.5.31 (http://www.hyphy.org/) (Kosakovsky Pond et al., 2020) to perform a series of selection analyses. This
version of HyPhy includes many optimizations that were introduced specifically to deal with large SARS-CoV-2 datasets; since
March 2020, targeted optimizations for trees withR 1,000 leaves allowed HyPhy to process 10-25 times as many sequences
as earlier versions.We performed SLAC (for substitutionmapping (Kosakovsky Pond and Frost, 2005)), FEL (for pervasive pos-
itive diversifying and negative selection detection (Kosakovsky Pond and Frost, 2005)), and MEME (for episodic positive diver-
sifying selection detection (Murrell et al., 2015)) analyses that were restricted to considering only mutationsmapping to internal
branches of inferred trees. These analyses reported p values and inferred dS and dN rates and ratios for individual codon sites.Lineage-specific dataset preparation
We used the RASCL tool (Lucaci et al., 2021) to perform a more detailed analysis of downsampled V1, V2, and V3 gene and gene-
segment datasets. For a given gene or gene segment we aligned all sequences from an individual lineage (i.e., V1, V2 or V3) and refer-
ence sequences (GISAID unique haplotypes in the corresponding gene/peptide encoding gene segment) to the GenBank reference
genome protein sequence for that gene/peptide encoding gene segment using bealign with the HIV-BETWEEN-F scoring matrix
which is optimized for low-diversity viral sequences.
Because the codon-based selection analyses that we performed gain no power from including identical sequences, and minimal
power from including sequences that are essentially identical, we filtered the V1, V2, V3, and reference (GISAID) sequences using
pairwise genetic distances complete linkage clustering with the tn93-cluster tool (https://github.com/veg/tn93; (Kosakovsky Pond
et al., 2018)). All groups of sequences that were withinD genetic distance (determined using a Tamura-Nei 93 nucleotide substitution
model) of every other sequence in the group were represented by a single randomly chosen sequence in the group. We set D at
0.0001 for lineage-specific sequence sets, and at 0.0015 for GISAID reference (or ‘‘background’’) sequence sets. We restricted
the reference sequence set to sequences sampled before 15 October 2020 since we were specifically interested in, on a lineage-
by-lineage basis, disentangling the impacts of selective processes operating before this date from those operating thereafter.
This date approximately marks what appears to have been a major shift in the selective environment within which SARS-CoV-2 is
evolving.
We inferred a maximum likelihood tree from the combined sequence dataset with raxml-ng (Kozlov et al., 2019) using default set-
tings (GTR+G nucleotide substitution model and 20 starting trees). We partitioned internal branches in the resulting tree into two non-
overlapping sets used for testing via encoded annotations made to the Newick tree. Because of low phylogenetic resolution in some
of the genes/peptide encoding segments, not all analyses were possible for all segments/genes. In particular this is true when lineage
V1, V2 or V3 sequences were not monophyletic in a specific gene/segment, and no internal branches could be labeled as belonging
to the foreground lineage.
Lineage-specific selection analyses
We used HyPhy v2.5.31 (http://www.hyphy.org/) (Kosakovsky Pond et al., 2020) to perform a series of selection analyses. As with the
analysis of global datasets we considered only internal-branch mutations in the lineage-specific selection analyses
We performed codon-site-level tests for episodic diversifying (MEME) (Murrell et al., 2015) and pervasive positive or negative se-
lection (FEL) (Kosakovsky Pond and Frost, 2005) on the internal branches of the V1,V2 or V3 clade datasets containing sequences
deposited in GISAID by 20 April 2021, to infer the selective dynamics at individual codon-sites across the different SARS-CoV2
genes. Analyses were run with default settings using–branches Internal command line flags to restrict dN/dS testing to internal
branches only. We only considered as significant those selection signals detected at codon-sites that did not contain nucleotides
expressed in multiple frames.
We performed model-based predictions of codons expected to arise in SARS-CoV-2 based on the evolution of related coronavi-
ruses in other host species was determined using the PRIME method http://hyphy.org/w/index.php/PRIME with default settings.
We combined the results of all these analyses using a Python script and visualized them using several open source libraries in an
ObservableHQ notebook (https://observablehq.com/@spond/n501y-clades).
Calculating mutation frequency changes
To calculate the relative ratio of a given mutation frequency (M) for a given time period, we utilized the curated variant dataset with
metadata based on GISAID sequences (see additional resources). We used the GISAID Pangolin annotation to extract sequences
assigned to the V1, V2 or V3 lineages discarding all sequences for which sampling dates were not recorded. Given a cutoff dateCell 184, 5189–5200.e1–e4, September 30, 2021 e3
ll
ArticleD, we binned all sequences into those collected prior to D, and at or after D. We next generated a 232 table (before/after D, with/
withoutmutationM), performed a chi-square test, and computed the relative ratio for RR(M) as the ratio ofmutation frequencies after /
before the cutoff date. P values from the test were adjusted using a conservative Bonferroni multiple testing correction, using the total
number of distinct mutations in a given gene as the number of tests. These calculations were carried out in a web-browser inside an
interactive notebook (https://observablehq.com/@spond/sc2-selection-trends)
Identification of potentially adaptive convergent mutations
We produced a list of 501Y lineage signature mutation sites at which mutations arising in viruses of any one of the 501Y lineages
during or before March 2021 converged on the signature mutation states of viruses in another 501Y lineage. To this list of sites
we added a list of non-signature mutation sites at which convergent mutations occurring beforeMarch 2021 were observed between
two or more different 501Y lineages that incurred enough convergent non-synonymous mutations along internal tree branches (i.e.,
excluding mutations mapping to terminal tree branches) to trigger positive selection signals with associated MEME or FEL p values <
0.05. We then tested this combined ‘‘convergence list’’ for evidence of its constituent convergent mutations having more than
doubled in frequencywithin V1, V2 or V3 sequences sampled between 15March and 01 June 2021 relative to frequencies seen within
these lineages before that time. We then repeated this test with 501Y lineage signature mutation sites at which convergent mutations
had not been detected prior to March 2021. Finally, all convergent mutations analyzed in these tests that (1) more than doubled in
frequency within individual 501Y lineages between 15 March 2021 and 01 June 2021, and (2) occurred at signature/non-signature
mutation sites displaying significant signals of positive selection in either the global SARS-CoV-2 sequence dataset (FEL p value <
0.05) or any one of the lineage-specific datasets (MEME/FEL p values < 0.05) were identified as themutations most likely to positively
impact the fitness of the 501Y lineage viruses. This list of mutations was merged with the list of deletion mutations that characterize
the different 501Y lineages and the three cardinal 501Y lineage signaturemutations, L18F, K417N/K andN501Ywhich, due to already
high frequencies in multiple 501Y lineages could not have doubled in frequency in more than a single lineage between 15 March and
01 June 2021. This final mutation list is what we called the 501Y meta-signature.
QUANTIFICATION AND STATISTICAL ANALYSIS
Comparative sequence analyses were conducted in HyPhy v2.5.31 as described in the method details section. Detection of individ-
ual sites subject to various selective forces were based on published approaches described in the original publications (cited in the
methods details section) with statistical significance based on likelihood ratio tests with asymptotic test statistic distributions;
p values used are reported in the text. Effective sample sizes for these tests are difficult to quantify, but the number of unique se-
quences and total tree branch lengths are both positively correlated with reduction in sampling variance of estimates (Scheffler
et al., 2014). Numbers of haplotypes and sequence divergence are available in the corresponding data repositories in the key re-
sources table.
ADDITIONAL RESOURCES
ObservableHQ notebook detailing N501Y lineage-specific selection results (other clades included as well): https://observablehq.
com/@spond/n501y-clades@3752
ObservableHQ notebook for calculating changes inmutation frequencies, relative frequency ratios, and selection profiles in SARS-
CoV-2 sequences: https://observablehq.com/@spond/sc2-selection-trends
ObservableHQ notebook for calculating selection strengths and profiles at individual sites using sliding window analysis: https://
observablehq.com/@spond/sc2-temporal-selection-trends
ObservableHQ notebook for displaying a combined view of sites under selection in N501Y clades: https://observablehq.com/@
spond/n501y-sites
ObservableHQ notebook for displaying a combined view of sites which may be experiencing convergence in N501Y clades:
https://observablehq.com/@spond/clade-convergencee4 Cell 184, 5189–5200.e1–e4, September 30, 2021
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Figure S1. Signals of positive selection at individual codon sites that were detectable with the FELmethod at different times betweenMarch
2020 and February 2021 applied to sequences sampled over 90-day intervals, related to Figure 2
The plotted date shows the end of the 90-day period. Genes with associated trees that have a total length shorter than 0.5 subs/site for a given time-period are not
shown. Note that for the ORF3a and the N gene the interpretation of positive selection signals is complicated by the fact that each of these genes encompasses
multiple smaller genes that are expressed in different reading frames. This is because synonymous substitutions in the ORF3a and N reading frames will be non-




Figure S2. Global selection trends at sites in 501Y lineage viruses that are either signature mutations or that, on April 20, 2021, displayed
evidence of both lineage-specific positive selection on internal tree branches andmutational convergence between viruses in different 501Y
lineages, related to Figure 3
Red dots indicate positive selection and blue dots indicate negative selection in the global SARS-CoV-2 dataset. The sizes of the dots indicate the strength of the
positive/negative selection signals. Selection signals indicate those detected when considering only the sequences sampled in the preceding three months.
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